全文获取类型
收费全文 | 1490篇 |
免费 | 111篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 57篇 |
妇产科学 | 8篇 |
基础医学 | 134篇 |
口腔科学 | 30篇 |
临床医学 | 203篇 |
内科学 | 251篇 |
皮肤病学 | 303篇 |
神经病学 | 49篇 |
特种医学 | 258篇 |
外科学 | 95篇 |
综合类 | 27篇 |
预防医学 | 78篇 |
眼科学 | 9篇 |
药学 | 40篇 |
中国医学 | 5篇 |
肿瘤学 | 54篇 |
出版年
2023年 | 10篇 |
2021年 | 16篇 |
2020年 | 8篇 |
2019年 | 14篇 |
2018年 | 34篇 |
2017年 | 16篇 |
2016年 | 24篇 |
2015年 | 27篇 |
2014年 | 41篇 |
2013年 | 36篇 |
2012年 | 30篇 |
2011年 | 38篇 |
2010年 | 49篇 |
2009年 | 76篇 |
2008年 | 50篇 |
2007年 | 32篇 |
2006年 | 30篇 |
2005年 | 21篇 |
2004年 | 24篇 |
2003年 | 22篇 |
2002年 | 21篇 |
2001年 | 30篇 |
2000年 | 16篇 |
1999年 | 19篇 |
1998年 | 54篇 |
1997年 | 56篇 |
1996年 | 71篇 |
1995年 | 55篇 |
1994年 | 49篇 |
1993年 | 49篇 |
1992年 | 45篇 |
1991年 | 21篇 |
1990年 | 44篇 |
1989年 | 58篇 |
1988年 | 47篇 |
1987年 | 48篇 |
1986年 | 48篇 |
1985年 | 44篇 |
1984年 | 36篇 |
1983年 | 20篇 |
1982年 | 26篇 |
1981年 | 19篇 |
1980年 | 13篇 |
1979年 | 10篇 |
1978年 | 8篇 |
1977年 | 14篇 |
1976年 | 18篇 |
1975年 | 17篇 |
1972年 | 8篇 |
1971年 | 9篇 |
排序方式: 共有1608条查询结果,搜索用时 31 毫秒
31.
Cyclosporine metabolism by P450IIIA in rat enterocytes--another determinant of oral bioavailability?
J C Kolars P L Stetson B D Rush M J Ruwart P Schmiedlin-Ren E A Duell J J Voorhees P B Watkins 《Transplantation》1992,53(3):596-602
Cyclosporine is converted to its major metabolites (M-17, M-1, and M-21) in human liver by enzymes belonging to the P450IIIA subfamily. These enzymes are also present in rat and human enterocytes; however, the possibility that CsA is metabolized in enterocytes has not been previously investigated. We therefore directly compared metabolism of 3H-CsA in microsomes prepared from liver and jejunal enterocytes. M-17, M-1, and M-21 were the major CsA metabolites produced by enterocyte microsomes. This metabolism appeared to be catalyzed by P450IIIA, because pretreatment of rats with the P450IIIA inducer dexamethasone significantly increased the rate of CsA metabolism in enterocyte microsomes and preincubation of enterocyte microsomes with anti-P450IIIA IgG inhibited the production of CsA metabolites by greater than 95%. To determine if enterocyte P450IIIA metabolizes CsA in vivo, rats were pretreated with the P450IIIA inducer dexamethasone, the P450IIIA inhibitor erythromycin, or vehicle alone. At laparotomy, 2 mg/kg of 3H-CsA was injected into a sealed loop of jejunum, and after collection of the mesenteric venous blood draining this segment for 45 min, the production of M-17 and M-1 was measured. In the control group, a mean of 3.9% of the recovered radioactivity was found as M-1 and M-17. In the rats pretreated with dexamethasone, a mean of 8.4% of the radioactivity was found as M-1 and M-17 (P less than 0.05 relative to control) and this decreased to 2.3% in the group pretreated with erythromycin (P = 0.08 relative to control). We conclude that P450IIIA in jejunal enterocytes readily metabolizes CsA. Furthermore, the metabolism of CsA by enterocytes in vivo is substantial and likely contributes to "first pass metabolism" of orally administered CsA. Our observations provide novel hypotheses to explain some important drug interactions and interpatient differences in CsA dosing requirements. 相似文献
32.
A S Josen E Giuliani A B Voorhees J M Ferrer 《Archives of surgery (Chicago, Ill. : 1960)》1976,111(9):980-986
Two hundred sixty-two patients with active upper gastrointestinal (GI) bleeding underwent panendoscopy between July 1970 and March 1973. There was 100% accuracy of endoscopic diagnosis as to the anatomical site of bleeding; the etiopathologic definition was 94.7% accurate. The series was divided into two groups, 116 with "liver disease" and 146 with "no liver disease." There were 107 patients with varices: 21 fell into no liver disease (small varices) and 86 into liver disease (39 small and 47 large varices). All had associated gastritis. Three endoscopic bleeding patterns were identified in the liver disease group. Only 27% of the patients in the liver disease group with varices (cirrhotics) had frank variceal hemorrhage, whereas 57% bled from hemorrhagic gastritis. The diagnostic unit provided early diagnosis, meaningful therapy, organized data gathering, and rough estimates of ultimate prognosis. 相似文献
33.
R Francavilla VL Miniello L Brunetti ME Lionetti L Armenio 《Acta paediatrica (Oslo, Norway : 1992)》2003,92(S441):101-104
A major complication of cholestasis is fat malabsorption related to decreased intestinal bile acids, which leads to malnutrition and fat-soluble vitamin deficiency. The impaired excretion of bile acids leads to a low intraluminal micellar concentration that causes long-chain triglyceride lipolysis and absorption to be ineffective. Medium-chain triglycerides (MCTs) are more readily absorbed when there are low concentrations of bile acids and therefore are a good source of fat calories; MCTs can be administered as MCT-containing formulas. In those children who are unable to take sufficient calories by mouth, it is important to start nocturnal enteral feeding to improve nutritional status. In infants with cholestasis, the absorption of fat-soluble vitamins (A, D, E and K) that require bile acids is also impaired, and supplementation is mandatory. Vitamin K deficiency may be responsible for hypoprothrombinaemia, which may lead to bleeding diathesis, Vitamin K (phytomenadione) should therefore be promptly administered intravenously, at a dose of 1 mg. Chronic vitamin E (α-tocopherol) deficiency is associated with a progressive neuromuscular syndrome that can cause cerebellar ataxia, areflexia and peripheral neuropathy. Supplements are given orally in doses of 3–5 times the normal requirement if cholestasis is incomplete. In complete cholestasis, supplements must be given intramuscularly at monthly intervals. In infants who fail to thrive, dietary supplements of carbohydrate polymers and MCTs are required. 相似文献
34.
中国健康志愿者单剂静滴甲磺酸加替沙星注射液的药代动力学 总被引:5,自引:0,他引:5
目的:研究中国健康成年男性志愿者单剂静滴甲磺酸加替沙星注射液的药代动力学。方法:按药物临床试验管理规范(GCP)指导原则设计试验方案。选择9名受试者分别依次单刘静滴100,200和400mg的甲磺酸加替沙星注射液后,应用HPLC测定血药浓度,采用3P97软件进行数据处理,求出药代动力学参数。结果:受试者分别给药后,药-时曲线符合二房室模型,主要药代动力学参数C_(max)分别为1.10±0.19,2.17±0.33和3.16±0.47mg·L~(-1);t_(1/2)β分别为7.42±1.99,8.41±2.72和8.46±2.83h;AUC_(0-∞)分别为4.45 ±0.71,11.10±1.81和23.03±3.83mg h·L~(-1)。原形药主要经肾排泄,48h尿药累积排泄率分别为(43.08±15.79)%,(51.33±23.69)%和(45.67±18.22)%。结论:9名静滴甲磺酸加替沙星注射液后,药-时曲线符合二房室模型。提示甲磺酸加替沙星在100~400mg剂量内药物体内过程基本呈线性动力学特征而无饱和性,主要排泄途径为肾脏。 相似文献
35.
原发性乳腺恶性淋巴瘤六例临床分析 总被引:8,自引:0,他引:8
目的 分析原发性乳腺恶性淋巴瘤的临床特点,探讨其诊断、分期和治疗方法。方法回顾分析我院自1995~2002年收治的6例原发性乳腺恶性淋巴瘤和1980~2002年国内主要文献报道的279例原发性乳腺恶性淋巴瘤的临床特征、诊断情况和治疗方法,进行对比分析。结果 285例病例均为非霍奇金淋巴瘤(NHL),免疫学检查证实有282例为B细胞源性(98.9%);女性268例,占94.0%;病灶位于右侧163例,占57.2%;Ⅰ期和Ⅱ期的原发性乳腺恶性淋巴瘤占89.8%。经手术、化疗、放疗等综合治疗后,生存期2~206个月,中位生存期最短23个月,最长56个月。结论 原发性乳腺恶性淋巴瘤绝大部分为B细胞源性非霍奇金淋巴瘤(NHL),Ⅰ期、Ⅱ期多见。对于原发性乳腺恶性淋巴瘤,诊断是关键,确诊后经手术、化疗、放疗等综合治疗,可以获得较长的生存期,疗效十分满意。 相似文献
36.
L Patel PE Clayton ME Jenney JE Ferguson TJ David 《Archives of disease in childhood》1997,76(6):505-508
Cross sectional studies have reported impaired growth in children with atopic dermatitis. If this growth impairment is irreversible, it would be expected to adversely influence final height attainment. The standing heights and other anthropometric parameters were assessed in 35 adults with onset of atopic dermatitis before 5 years of age and a control group of 35 adults with adult onset contact dermatitis or psoriasis. There was no significant difference in the standing height SD score, mid-parental height SD score, sitting height SD score, subischial leg length SD score, nor body mass index between the atopic dermatitis and control groups. The standing height SD score was not significantly different among: (a) patients with atopic dermatitis affecting less than 50% of their body surface area and those with greater than 50% affected; (b) patients using the four different potency topical corticosteroids; and (c) patients with atopic dermatitis without asthma and those with coexisting asthma. It is concluded that short stature is not a feature of our group of adult patients with onset of atopic dermatitis before 5 years of age, continuing into adulthood, and severe enough to require specialist care. This suggests that if growth impairment occurs in childhood, it is likely to be temporary and reversible. 相似文献
37.
ANA JP MORAES POLLYANA MF SOARES AURA L ZAPATA ANA PN LOTITO ADRIANA ME SALLUM CLOVIS AA SILVA 《Pediatrics international》2006,48(1):48-53
Background: The purpose of the present paper was to describe the clinical manifestations and treatment of patients with panniculitis. Methods: From January 1983 to December 2002, 4294 patients were treated for pediatric rheumatological diseases at Pediatric Rheumatology Unit, University of São Paulo, Brazil. Of these, 35 children and adolescents (0.8%) presented with panniculitis: erythema nodosum (EN) or Weber–Christian disease (WCD). Clinical characteristics, laboratory exams, biopsy of the lesion, treatment and clinical course were studied. Results: Of the 35 patients, 29 presented with EN and six with WCD, one of these with cytophagic histiocytic panniculitis. Mean age at symptom onset was 85 months (6–204 months) and the mean duration of follow up was 55 months (1–144 months). All the patients presented with inflammatory subcutaneous nodules. The patients with WCD presented with systemic manifestations and cutaneous atrophy. The principal etiologies of EN were streptococcal infection (42%), undetermined (13.5%), pulmonary tuberculosis (10%), and acute rheumatic fever (10%). Biopsy of the nodules indicated septal panniculitis in 14 patients with EN and lobular panniculitis without vasculitis in the patients with WCD, one of which had cytophagic histiocytic panniculitis. There was recurrence in 11 patients (38%) with EN and in all those with WCD. Non‐steroidal anti‐inflammatory drugs were used in 15 patients with EN and corticosteroids and/or immunosuppressive drugs in the six patients with WCD. Three patients died. Conclusions: EN is the most frequent panniculitis, with a benign course and is mainly associated with infections. WCD is a severe disease, with systemic involvement, that proceeds with cutaneous atrophy and requires the use of corticosteroids and or immunosuppressive drugs. 相似文献
38.
Stroke survivors’ and carers’ experiences of a systematic voiding programme to treat urinary incontinence after stroke
下载免费PDF全文
![点击此处可从《Journal of clinical nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
39.
40.
Screening of candidate biomaterials for alveolar augmentation using a critical‐size rat calvaria defect model
下载免费PDF全文
![点击此处可从《Journal of clinical periodontology》网站下载免费的PDF全文](/ch/ext_images/free.gif)